Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy
Open Access
- 21 July 2022
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (4) , 1429-1437
Abstract
No abstract availableKeywords
Funding Information
- Narodowa Agencja Wymiany Akademickiej (PNN/IWA/2019/00057)
- American Cancer Society (129784-IRG-16-188-38-IRG)
- National Cancer Institute (R01 CA241661, R37 CA244911)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK123049)
- Burroughs Wellcome Fund
- Canadian Aeronautics and Space Institute
- National Institutes of Health (DP2 TR002776)
- National Science Foundation
This publication has 52 references indexed in Scilit:
- How does doxorubicin work?eLife, 2012
- In Vitro–In Vivo Translation of Lipid Nanoparticles for Hepatocellular siRNA DeliveryACS Nano, 2012
- Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in ratBiomaterials, 2012
- Co‐delivery of Doxorubicin and Bcl‐2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug‐Resistant Cancer CellsSmall, 2009
- Control of mitochondrial apoptosis by the Bcl-2 familyJournal of Cell Science, 2009
- Bcl-2 family proteins and cancerOncogene, 2008
- A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)Investigational New Drugs, 2007
- Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemiaBlood, 2003
- Emerging roles of caspase-3 in apoptosisCell Death & Differentiation, 1999
- Involvement of the bcl -2 Gene in Human Follicular LymphomaScience, 1985